Clinical significance of serum hyaluronan levels in systemic sclerosis: Association with disease severity

Journal of Rheumatology

Volumn 35, Issue 9, 2008, Pages 1825-1829

  Yoshizaki, Ayumi ^a   Iwata, Yohei ^a   Komura, Kazuhiro ^a   Hara, Toshihide ^a   Ogawa, Fumihide ^a   Muroi, Eiji ^a   Takenaka, Motoi ^a   Shimizu, Kazuhiro ^a   Hasegawa, Minoru ^b   Fujimoto, Manabu ^b   Sato, Shinichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Fibrosis; Hyaluronan; Immune system; Systemic sclerosis

Indexed keywords

HYALURONIC ACID;

ADULT; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; HEALTH STATUS; HUMANS; HYALURONIC ACID; MALE; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

EID: 54049107801     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003;120:542-7.
2. Neudecker BA, Stern R, Connolly MK. Aberrant serum hyaluronan and hyaluronidase levels in scleroderma. Br J Dermatol 2004;150:469-76.
3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
4. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35.
5. Levesque H, Baudot N, Delpech B, et al. Clinical correlations and prognosis based on hyaluronic acid serum levels in patients with progressive systemic sclerosis. Br J Dermatol 1991;124:423-8.
6. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004;279:17079-84.
7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
8. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
9. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
10. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis: association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
11. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005;11:1173-9.
12. Nishijima C, Sato S, Hasegawa M, et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology Oxford 2001;40:406-9.
13. Lin KI, Kao YY, Kuo HK, et al. Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1. J Biol Chem 2006;281:24111-23.
14. Fu SL, Hsu YH, Lee PY, et al. Dioscorin isolated from Dioscorea alata activates TLR4-signaling pathways and induces cytokine expression in macrophages. Biochem Biophys Res Commun 2006;339:137-44.
15. Thorn CF, Lu ZY, Whitehead AS. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 2004;59:152-8.